Table 2 Type and length of treatment courses.
From: Long-term treatment with subcutaneous immunoglobulin in multifocal motor neuropathy
Pt | First line treatment (FLT) | FLT duration (years) | FLT efficacy | Second and third line treatment | Second and third treatment efficacy | IVIG duration (years) |
|---|---|---|---|---|---|---|
1 | IVIG | 6 | Yes (stabilization) | – | – | 6 |
2 | Ciclophosfamide | 6 | Yes (complete regression) | IVIG | Yes | 4 |
3 | IVIG | 3 | Yes (initial almost complete regression) | – | – | 3 |
4 | Ciclophosfamide | 0.5 | Yes (almost complete regression) | (1) AZT, (2) interferon beta, (3) IVIG | Partial/no/yes | 19 |
5 | IVIG | 7 | Yes (initial complete regression, then partial benefit) | – | – | 7 |
6 | Ciclophosfamide | 12 | Yes (almost complete regression) | (1) Rituximab, (2) IVIG | Partial/yes | 2 |
7 | IVIG | 1 | Yes (initial almost complete regression) | – | – | 1 |
8 | IVIG | 6 | Yes (stabilization) | – | – | 6 |
